companydata.dkPerfusion Tech ApS: Financial statements 2025
CVR: 38238213
Perfusion Tech ApS (CVR 38238213) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -6,142,804 and a net result of DKK -12,724,708 compared with DKK -14,469,520 the year before. Equity amounted to DKK -9,640,655. The company had 11 employees in the financial year.
- Gross Profit
- -6,142,804 kr.
- Profit/Loss
- -12,724,708 kr.
- Equity
- -9,640,655 kr.
- Total Assets
- 4,586,810 kr.
- Employees
- 11
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | -6.1 mio. | -12.7 mio. | -9.6 mio. | 11 |
| 2024 | - | -9 mio. | -14.5 mio. | 2.1 mio. | 11 |
| 2023 | - | -5.4 mio. | -9.5 mio. | 2.9 mio. | 8 |
| 2022 | - | -4.2 mio. | -6.6 mio. | 1.2 mio. | 7 |
| 2021 | - | -1.1 mio. | -2.1 mio. | -3.9 mio. | 4 |
Find more companies like Perfusion Tech ApS
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorEvents in 2025
As of September 29, 2025, Declan Cassells is registered as director of Perfusion Tech ApS.
As of September 29, 2025, Pernille Charlotte Singer has stepped down as adm. dir. of Perfusion Tech ApS.
Perfusion Tech ApS has published its annual report for 2024. Gross profit came to DKK -9,021,930, and the net result was DKK -14,469,520.
As of June 4, 2025, Jeppe Øvli Øvlesen has left the board of directors of Perfusion Tech ApS.
As of June 4, 2025, Henrik Christensen has left the board of directors of Perfusion Tech ApS.
As of June 4, 2025, Thomas Engelbrecht Nordkild Jonassen has left the board of directors of Perfusion Tech ApS.
As of June 4, 2025, Mads Aagaard Linde Madsen has left the board of directors of Perfusion Tech ApS.
As of June 4, 2025, is registered as an owner of Perfusion Tech ApS with an ownership share of 100%.
As of April 22, 2025, Sten Scheibye has left the board of directors of Perfusion Tech ApS.
About Perfusion Tech ApS
Perfusion Tech ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2016. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Perfusion Tech IVS. The management consists of Declan Cassells. The company is owned by Renew Pharmaceuticals Limited. In 2025, the company reported a gross profit of DKK -6,142,804 and a net result of DKK -12,724,708 compared with DKK -14,469,520 the year before. Equity amounted to DKK -9,640,655.